Results 81 to 90 of about 2,275,397 (311)
Molecular Oncology, EarlyView.This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti +10 more
wiley +1 more source
An Index to the Biographical Notices, papers on the History of Medicine, and Reviews of Books on that subject, which have appeared in the Irish Journal of Medical Science from September, 1916 to December, 1954 [PDF]
, 1955 J. D. H. Widdess
openalex +1 more source
Centaur: Essays on the History of Medical Ideas. [PDF]
, 1959 William B. Bean
openalex +2 more sources
History of Medical Organization. [PDF]
JAMA: The Journal of the American Medical Association, 1905 Burlington, Iowa, April 16, 1905. To the Editor: —In "An Epitome of the History of Medical Organization in the United States," published inThe Journal, April 15, I note a statement concerning Iowa which may be misleading and I ask space for this, a more explicit account.
openaire +3 more sources
Inhibitor of DNA binding‐1 is a key regulator of cancer cell vasculogenic mimicry
Molecular Oncology, EarlyView.Elevated expression of transcriptional regulator inhibitor of DNA binding 1 (ID1) promoted cancer cell‐mediated vasculogenic mimicry (VM) through regulation of pro‐angiogenic and pro‐cancerous genes (e.g. VE‐cadherin (CDH5), TIE2, MMP9, DKK1). Higher ID1 expression also increased metastases to the lung and the liver.
Emma J. Thompson +11 more
wiley +1 more source
Medical Library Association Handbook of Medical Library Practice with a Bibliography of the Reference Works and Histories in Medicine and the Allied Sciences [PDF]
, 1956 openalex +1 more source
Molecular Oncology, EarlyView.Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu +11 more
wiley +1 more source
Molecular Oncology, EarlyView.This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani +14 more
wiley +1 more source
Molecular Oncology, EarlyView.B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez +17 more
wiley +1 more source